Six-year overall survival results added to u.s. prescribing information for adcetris® (brentuximab vedotin) as first-line treatment for advanced hodgkin lymphoma

Bothell, wash.--(business wire)--seagen inc. (nasdaq: sgen) today announced an update to the u.s. prescribing information (pi) for adcetris® (brentuximab vedotin) to include six-year overall survival results from the phase 3 echelon-1 clinical trial of adcetris plus combination chemotherapy in patients with previously untreated stage iii or iv classical hodgkin lymphoma compared to chemotherapy alone. the statistically significant data were presented last year at the annual meetings of the amer.
SGEN Ratings Summary
SGEN Quant Ranking